Welcome to our dedicated page for FEMASYS news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on FEMASYS stock.
Femasys Inc. (NASDAQ: FEMY) generates frequent news flow as a biomedical company focused on women’s reproductive health, fertility treatment and non-surgical permanent birth control. News updates commonly highlight progress across its product portfolio, including FemaSeed Intratubal Insemination, FemVue and FemVue Controlled diagnostic devices, FemBloc permanent birth control, and the FemChec diagnostic product.
Investors following FEMY news can expect coverage of regulatory milestones, such as U.S. FDA 510(k) clearance for FemVue Controlled and Investigational Device Exemption approval to advance the final phase of the FINALE pivotal trial for FemBloc. Company announcements also report international approvals for FemBloc in Europe, the UK and New Zealand, as well as the launch of post-market surveillance studies under EU Medical Device Regulation.
Femasys news releases frequently describe commercialization developments, including partnerships with distributors like Kebomed to expand FemBloc access in France and the Benelux region, initial commercial orders in European markets, and collaborations with healthcare providers such as Refuah Health Center to offer FemaSeed as a first-line infertility treatment in community-based care. Financial and capital markets updates, including quarterly results, underwritten offerings, and private placements of senior secured convertible notes and warrants, are also disclosed through press releases and related SEC filings.
This FEMY news page aggregates these updates in one place, making it easier to track clinical progress, regulatory events, commercialization agreements, and listing-related notices from Nasdaq. Readers can use this feed to review how Femasys is executing on its women’s health strategy and how new information may relate to the company’s fertility and permanent birth control portfolio over time.
Femasys Inc. (NASDAQ: FEMY) announced that CEO Kathy Lee-Sepsick will present at The MedTech Conference on September 30, 2021, in Minneapolis. She will be part of a panel discussion titled “Early-Stage Medtech and Going Public,” scheduled from 10:00 to 10:35 a.m. ET. The conference runs from September 21 to 30, 2021, and focuses on advancements in medical technology. Femasys aims to address women’s health needs with innovative products, including FemBloc® and FemaSeed™. The company is committed to developing minimally invasive solutions for reproductive health.
Femasys Inc. (NASDAQ: FEMY) announced its inclusion in the Russell Microcap® Index, effective September 20, 2021. This recognition enhances the company's visibility in the global investment community and is expected to benefit stockholders. The CEO, Kathy Lee-Sepsick, highlighted the significance of this milestone following their IPO in June. The company aims to advance its product candidates, including FemBloc® and FemaSeed™, which target women’s healthcare needs through innovative, minimally invasive technologies. Membership in the index will last for one year.
Femasys Inc. (NASDAQ: FEMY) has appointed Dr. Edward G. Evantash as its new Chief Medical Officer, bringing over 20 years of experience in medical affairs, particularly in women's healthcare. Dr. Evantash, previously with Alydia Health and Hologic, will lead Femasys' clinical development programs, including advancing the late-stage candidates, FemaSeed™ and FemBloc®. His expertise aims to address unmet needs in reproductive health and enhance Femasys' strategic initiatives, particularly in clinical trial execution and FDA submissions.
Femasys Inc. (NASDAQ: FEMY) announced its IPO, raising $31.6 million, and appointed Anne Morrissey to its Board of Directors. The company initiated a pivotal LOCAL trial for its FemaSeed™ product with 792 patients enrolled. In Q2 2021, Femasys reported a 77.9% increase in FemVue sales, totaling $326,006. However, net loss for the quarter decreased to $1,083,059, or $0.52 per diluted share. The company aims to leverage its IPO proceeds to sustain operations through at least 2022, despite ongoing increases in general and administrative expenses.
Femasys Inc. (NASDAQ: FEMY) has initiated a pivotal trial for its innovative infertility treatment, FemaSeed, which features localized directional insemination. The trial, named LOCAL, aims to enroll up to 792 patients across 20 U.S. centers to evaluate safety and effectiveness. The trial's primary endpoints are clinical pregnancy rates and safety measures over a duration of seven weeks. This initiative underscores Femasys' commitment to providing cost-effective, less invasive infertility solutions amid a growing public health concern.
On June 21, 2021, Chardan announced its role as the lead left bookrunner for the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY), a biomedical company dedicated to women's healthcare. The funds raised will support Femasys’ clinical trials for its FemBloc and FemaSeed systems, along with product development and hiring efforts. Chardan has prioritized investing in healthcare companies addressing significant unmet needs, reflecting a commitment to ESG principles.